European Medicines Agency recommends that next season’s Covid-19 vaccines target XFG variant
Sign up now: Get ST's newsletters delivered to your inbox
Covid-19 vaccines still help prevent severe disease and death, but updating shots to better match circulating variants can improve protection as the virus changes.
PHOTO: REUTERS
The European Medicines Agency (EMA) said on May 29 that the Covid-19 vaccines for the 2026 to 2027 vaccination campaign in Europe should preferably be updated to target the XFG variant.
The decision aligns with the US Food and Drug Administration’s (FDA) advisory panel, which on May 28 voted in favour of the same target for next season’s shots.
The recommendation, issued by EMA’s Emergency Task Force, is meant to guide vaccine makers preparing Covid-19 shots for the next winter season in the European Union and the European Economic Area.
EMA said XFG is the preferred choice within the current Omicron-related variant family, though closely related variants such as LP.8.1 could also be considered.
Covid-19 vaccines still help prevent severe disease and death, but updating shots to better match circulating variants can improve protection as the virus changes, EMA said.
XFG, NB.1.8.1 and BA.3.2 are circulating in Europe, with no single variant clearly dominant across countries.
The agency said vaccines targeting XFG are expected to also protect against BA.3.2, though the recommendation could change if the virus situation shifts significantly.
Vaccine makers are expected to keep collecting data on how well updated shots work after approval, including data on protection and immune response. REUTERS
